StockWatch
·
Laboratory Analytical Instruments
New LaunchJul 28, 2026, 04:13 PM

Alamar Launches NULISAseq Immune 340 Panel for Immune Profiling

AI Summary

Alamar Biosciences, Inc. announced the launch of its NULISAseq™ Immune 340 Panel, an advanced multiplexed immune profiling solution. This new panel expands on previous offerings to simultaneously measure approximately 340 immune-related proteins from a single sample, including low-abundance targets often missed by standard platforms. The company believes this will deepen the understanding of the immune system in critical disease areas like cancer, cardiovascular, metabolic, and autoimmune diseases, accelerating biomarker discovery and drug development.

Key Highlights

  • Alamar Biosciences launched the NULISAseq™ Immune 340 Panel for translational research and drug development.
  • The panel expands on the NULISAseq Inflammation Panel 250, measuring approximately 340 immune-related proteins.
  • It enables simultaneous measurement of proteins from a single sample, including those previously undetectable.
  • The panel provides a deeper understanding of the immune proteome in cancer, cardiovascular, metabolic, autoimmune diseases, and aging.
  • It offers ultra-high sensitivity to detect low abundance targets like checkpoint inhibitors and regulatory proteins.
  • The technology aims to accelerate biomarker discovery and strengthen new therapy and diagnostic development.